Scholarlink

<p>Castration-resistant prostate cancer (CRPC) is a stage of prostate cancer that is progressed and resistant to treatment. Intra-tumoral androgen production, as well as substantial metabolic reprogramming, present significant treatment hurdles. <i>De novo</i> lipogenesis (DNL) is emerging as a key metabolic signature of CRPC, supporting tumour development, intra-tumoral androgen synthesis, membrane biosynthesis, energy production, and oncogenic signaling. Importantly, lipogenesis in CRPC is supported by upstream metabolic feeders such as increased glycolysis, rewired tricarboxylic acid (TCA) cycle activity, and amino acid metabolism, which work altogether to provide a steady supply of lipid and sterol precursors. This review summarizes the metabolic crosstalk linking Glucose to sterols in CRPC progression and highlights how these pathways cooperate to maintain androgen biosynthesis and therapeutic resistance. In addition, we highlight the emerging role of phytochemicals as multi-target metabolic modulators capable of suppressing overactivated lipogenesis, thereby reducing treatment-associated toxicity. Overall, this review highlights lipogenesis-centered metabolic targeting as a promising strategy to overcome metabolic plasticity, minimize conventional drug dosage and achieve therapy durability in CRPC, especially through logical combination techniques using phytochemical adjuvants.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rewired lipid metabolism in castration-resistant prostate cancer: molecular interplay between glucose metabolism and sterol synthesis

  • 期刊论文

  • 发表日期：

    2026年4月28日

查看全文
  • Harini Priyadharshini K B,
  • Sumathy Arockiasamy,
  • Sriram Krishnamoorthy

摘要

Castration-resistant prostate cancer (CRPC) is a stage of prostate cancer that is progressed and resistant to treatment. Intra-tumoral androgen production, as well as substantial metabolic reprogramming, present significant treatment hurdles. De novo lipogenesis (DNL) is emerging as a key metabolic signature of CRPC, supporting tumour development, intra-tumoral androgen synthesis, membrane biosynthesis, energy production, and oncogenic signaling. Importantly, lipogenesis in CRPC is supported by upstream metabolic feeders such as increased glycolysis, rewired tricarboxylic acid (TCA) cycle activity, and amino acid metabolism, which work altogether to provide a steady supply of lipid and sterol precursors. This review summarizes the metabolic crosstalk linking Glucose to sterols in CRPC progression and highlights how these pathways cooperate to maintain androgen biosynthesis and therapeutic resistance. In addition, we highlight the emerging role of phytochemicals as multi-target metabolic modulators capable of suppressing overactivated lipogenesis, thereby reducing treatment-associated toxicity. Overall, this review highlights lipogenesis-centered metabolic targeting as a promising strategy to overcome metabolic plasticity, minimize conventional drug dosage and achieve therapy durability in CRPC, especially through logical combination techniques using phytochemical adjuvants.